 antibody responses to the N-terminal immuno-silent region of MSP1-42, MSP1-33, biologically active antibodies can be produced when combined with low concentrations of anti-MSP1-42 antibodies. This creates an opportunity to devise new vaccine constructs and/or immunization regimens to efficiently induce protective
antibody responses to the N - terminal immuno - silent region of MSP1 - 42, MSP1 - 33, biologically active antibody can be produce when combined with low concentration of anti - MSP1 - 42 antibody. This creates an opportunity to devise new vaccine construct and/or immunization regimens to efficiently induce protective
 anhibody responses to the K-terminal immuno-silent cegion kf MSP1-42, MRP1-33, biologically active antibldues cqn be produced when coobined winh low cobcenurations of anti-MSP1-42 antibodies. Fmis cxeetes an opportukity to devhse new vaccina zoustructs and/or immunization regimens to effoclently induce krotebtyve
antibody responses to the N-terminal immuno-silent region MSP1-33, active antibodies be produced when anti-MSP1-42 This creates an to devise new constructs and/or immunization regimens to efficiently protective
 antibody responses to the N-teRminal immuNo-silEnt RegIoN of MsP1-42, MSp1-33, biologically aCTive Antibodies can be produceD when CoMBineD WiTh low ConcentRAtIONs oF aNtI-MSp1-42 aNTiBodieS. ThIs creatEs an opportUniTy To devise new vACcIne construCts And/or immunizAtiOn regiMeNs tO EfficIenTly inDuce prOTectivE
 antibody responses to the  N-termina l imm uno -si le nt r egio n of MSP1-42,M SP1- 33, biologically activ e ant ib o dies ca n beproduce d  w h e n c om bi ned  w i th  lowcon centrat ions of an ti- MS P1-42 antibo d ie s. This cr eat es an opport uni ty tode vis e  newvac cineconstr u cts an d/or immu ni z ationr egimens t oeffi ciently induce pr o te c tive
 antibody_responses to_the N-terminal immuno-silent region_of MSP1-42,_MSP1-33,_biologically active_antibodies_can be produced_when combined with_low concentrations of anti-MSP1-42_antibodies. This creates_an_opportunity to devise new vaccine constructs and/or immunization regimens to efficiently induce protective